|Bid||14.40 x 0|
|Ask||14.48 x 0|
|Day's range||14.33 - 14.47|
|52-week range||8.94 - 14.47|
|PE ratio (TTM)||72.82|
|Forward dividend & yield||0.18 (1.40%)|
|1y target est||10.06|
ResMed's (RMD) wholly owned unit Brightree remains integral to the company's group for two full years with a consistent stretch of success.
NEW YORK, June 18, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The ...
Peter Farrell named as Chairman of the Board, Dr. Pad Chivukula reinstated as CSO and COO. SAN DIEGO, May 31, 2018-- Arcturus Therapeutics Ltd., a leading RNA medicines company, today announced that Dr....
Integration of HEALTHCAREfirst's solutions suite with ResMed's (RMD) SaaS portfolio will help manage the burgeoning population and provide benefits to patients.
With a view to consistently lead the SDB market and boost the company's sales, ResMed (RMD) sets sights on product development and innovation.
Arcturus Therapeutics Ltd. (ARCT) (“Arcturus” or the “Company), a leading RNA medicines company, today announced that, as part of a settlement agreement, it has appointed four new independent directors, Dr. Peter Farrell, Mr. Andrew Sassine, Mr. James Barlow and Dr. Magda Marquet, to its Board, effective as of May 27, 2018. In connection with these appointments, Dr. Stuart Collinson, Mr. Daniel Geffken, Dr. David Shapiro, and Mr. Craig Willett have resigned from the Board.
ResMed (RMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Fisher & Paykel Healthcare Corp Ltd (ASX:FPH) share price has sunk lower after the release of a strong full-year result. But is this the reason its shares are sinking lower?
ResMed (RMD) presents the company-sponsored health economic studies, Home Oxygen Therapy-Home Mechanical Ventilation (HOT-HMV), at the ATS 2018 International Conference.
Companies like Broadcom Ltd. and Norwegian Cruise Line Holdings Ltd. are adding back millions in “ghost revenue” — deferred revenue that accounting standards force them to write off after an acquisition — when calculating executive bonuses, an issue that is taking on new resonance after a former Symantec Corp. employee complained about the practice internally and prompted an audit committee investigation.